Lake Street Initiates Coverage On Aytu BioPharma with Buy Rating, Announces Price Target of $8

Benzinga · 07/01 14:47
Lake Street analyst Thomas Flaten initiates coverage on Aytu BioPharma (NASDAQ:AYTU) with a Buy rating and announces Price Target of $8.